The evolution and impact of the American College of Chest Physicians consensus statement on antithrombotic therapy

Clinics in Chest Medicine

Volumn 24, Issue 1, 2003, Pages 139-151

  Tapson, Victor F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DEXTRAN; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DEVICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ELASTIC STOCKINGS; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HUMAN; INTERMITTENT PNEUMATIC COMPRESSION; LUNG EMBOLISM; MEDICAL SOCIETY; PRIORITY JOURNAL; REVIEW; VEIN THROMBOSIS;

EID: 0037346359     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(02)00079-5     Document Type: Review

References (68)

1. ACCP/NHLBI National Conference on Antithrombotic Therapy. Chest 1986;89(Suppl):1S-106S.
2. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1986;89(2 Suppl):2S-3S.
3. Cook DJ, Guyatt GH, Laupacis A, et al. Clinical recommendations using levels of evidence for antithrombotic agents. Chest 1995;108(Suppl):227S-30S.
4. Guyatt GH, Cook DJ, Sackett DL, et al. Grades of recommendations for antithrombotic agents. Chest 1998;114(Suppl):441S-4S.
5. Guyatt GH, Sackett DL, Sinclair J, et al. Users' guide to the medical literature: IX. A method for grading health-care recommendations. JAMA 1995;274:1800-4.
6. Guyatt GH, Schunemann H, Cook D, et al. Grades of recommendation for antithrombotic agents. Chest 2001;119(Suppl):3S-7S.
7. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1986; 89(Suppl):26S-35S.
8. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960;1:1309-12.
9. Hunter RB, Walker W. Anticoagulant drugs in the treatment of pulmonary embolism [letter]. Lancet 1960;2:206.
10. Brandjes DP, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-9.
11. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315: 1109-14.
12. Gallus A, Jackaman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986;2:1293-6.
13. Holmgren K, Andersson G, Fagrell B, et al. One month versus six month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985;218:279-84.
14. Enger E, Boysen S. Long-term anticoagulant therapy in patients with cerebral infarction. Acta Med Scand 1965;178(Suppl):7-55.
15. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants: mechanism of clinical action, clinical effectiveness, and optimal therapeutic range. Chest 1992;102(Suppl):312S-26S.
16. Dalen JE, Hirsh J, Deykin D, et al. Oral anticoagulants: mechanism of clinical action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108(Suppl):231S-46S.
17. Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:325-7.
18. Wheeler AP, Jaquiss RD, Newman JH. Physician practices in the treatment of venous thromboembolism. Arch Intern Med 1988;148:1321-5.
19. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-4.
20. Hull RD, Raskob GE, Lemaire J, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152:1589-95.
21. Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119:104-9.
22. Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991;151:333-7.
23. Raschke RA, Gollihare B, Peirce JC. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch Intern Med 1996;156:1645-9.
24. Johnson EA, Kirkwood TBL, Stirling Y, et al. Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous heparin after subcutaneous injection. Thromb Haemost 1976;35:586-91.
25. Andersson LO, Barrowcliffe TW, Holmer E, et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976;9:575-83.
26. Clagett GP, Salzman EW, Wheeler HB, et al. Prevention of venous thromboembolism. Chest 1992;102(Suppl): 391S-407S.
27. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998;114(Suppl):561S-78S.
28. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119(Suppl):176S-93S.
29. Levine M, Jent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
30. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334:682-7.
31. Gould MK, Dembitzer AD, Sanders GD, et al. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A cost-effectiveness analysis. Ann Intern Med 1999;130:789-99.
32. Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998; 158:1809-12.
33. Meignan M, Rosso J, Gauthier H, et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med 2000;160:159-64.
34. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-8.
35. Schulman S, Rhedin A-S, Lindmaker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of idiopathic venous thromboembolism. N Engl J Med 1995;332: 1661-5.
36. Kearon C, Gent M, Hirsh J, et al. Extended anticoagulation prevented recurrence after a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340:901-7.
37. The Urokinase Pulmonary Embolism Trial: a national cooperative study. Circulation 1973;47(Suppl):1-100.
38. Ohman EM, Harrington RA, Cannon CP, et al. Intravenous thrombolysis in acute myocardial infarction. Chest 2001;119(Suppl):253S-77S.
39. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143-50.
40. Greenfield LJ, Michna BA. Twelve year clinical experience with the Greenfield vena cava filter. Surgery 1988;104:706-12.
41. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119(Suppl): 132S-75S.
42. Kline A, Hughes LE, Campbell H, et al. Dextran 70 in prophylaxis of thromboembolic disease after surgery: a clinically oriented randomized, double-blind trial. BMJ 1975;2:109-12.
43. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994;308:235-46.
44. Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of VTE after surgery for fractured hip. Arch Intern Med 1989;149:771-4.
45. Graor RA, Stewart JH, Lotke PA, et al. RD heparin (ardeparin sodium) vs aspirin to prevent deep venous thrombosis after hip or knee replacement surgery. Chest 1992;102:118S.
46. Lotke PA, Palevsky H, Keenan AM, et al. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop 1996;324:251-8.
47. Perez JV, Warwick DJ, Case CP, et al. Death after proximal femoral fracture: an autopsy study. Injury 1995;26:237-40.
48. MacMahon S, Rodgers A, Collins R, et al. Antiplatelet therapy to prevent thrombosis after hip fracture: rationale for a randomised trial. J Bone Joint Surg 1994;76: 521-4.
49. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group (2000). Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355:1295-302.
50. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone J Surg 2001;83A:336-45.
51. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-80.
52. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia (HIT) in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
53. Butson ARC. Intermittent pneumatic calf compression for prevention of deep venous thrombosis in general abdominal surgery. Am J Surg 1981;142:525-7.
54. Hills NH, Pflug JJ, Jeyasingh K, et al. Prevention of deep vein thrombosis by intermittent pneumatic compression of the calf. BMJ 1972;1:131-5.
55. Moser G, Krahenbuhl B, Barroussel R, et al. Mechanical versus pharmacologic prevention of deep venous thrombosis. Surg Gynecol Obstet 1981;152: 448-50.
56. Wells PS, Lensing AWA, Hirsh J. Graduated compression stockings in the prevention of postoperative VTE: a meta-analysis. Arch Intern Med 1994;154:67-72.
57. Turner GM, Cole SE, Brooks JH. The efficacy of graduated compression stockings in the prevention of deep vein thrombosis after major gynaecological surgery. Br J Obstet Gynaecol 1984;91:588-91.
58. Allan A, Williams JT, Bolton JP, et al. The use of graduated compression stockings in the prevention of postoperative deep vein thrombosis. Br J Surg 1983;70:172-4.
59. Verstraete M, Prentice CRM, Samama M, et al. A European view on the North American Fifth Consensus on Antithrombotic Therapy. Chest 2000;117: 1755-70.
60. Nicolaides AN. Prevention of venous thromboembolism: European consensus statement. International Angiology 1992;11:151-9.
61. Nicolaides AN, Berqvist D, Hull RD. Prevention of venous thromboembolism: International consensus statement. International Angiology 1997;16:1-38.
62. Goldhaber SZ, Dunn K, MacDougall RC. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest 2000;118:1680-4.
63. Stratton MA, Anderson FA, Bussey HI, et al. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med 2000;160:4-40.
64. Bratzler DW, Raskob GE, Murray CK, et al. Underuse of venous thromboembolism prophylaxis for general surgery patients: physicians practices in the community hospital setting. Arch Intern Med 1998;158:1909-12.
65. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest 2001;120:1964-71.
66. Wen DY, Hall WA. Complications of subcutaneous low-dose heparin therapy in neurosurgical patients. Surg Neurol 1998;50:521-5.
67. Macdonald RL, Amidei C, Lin G, et al. Safety of perioperative subcutaneous heparin for prophylaxis of VTE in patients undergoing craniotomy. Neurosurgery 1999;45:245-52.
68. McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age Ageing 1986;15:84-8.